Sphingosine Kinases as Druggable Targets

Susan Pyne, David Roger Adams, Nigel J. Pyne

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

Abstract

There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid sphingosine 1-phosphate, are involved in pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
Place of PublicationBerlin
PublisherSpringer
Number of pages28
DOIs
Publication statusE-pub ahead of print - 20 Feb 2018

Publication series

NameHandbook of Experimental Pharmacology
ISSN (Print)0171-2004

Fingerprint

Sphingosine
Enzymes
Pulmonary Hypertension
Protein Isoforms
Binding Sites
Inflammation
Lipids
sphingosine kinase
Neoplasms
sphingosine 1-phosphate

Cite this

Pyne, S., Adams, D. R., & Pyne, N. J. (2018). Sphingosine Kinases as Druggable Targets. In Handbook of Experimental Pharmacology (Handbook of Experimental Pharmacology). Berlin: Springer. https://doi.org/10.1007/164_2018_96
Pyne, Susan ; Adams, David Roger ; Pyne, Nigel J. / Sphingosine Kinases as Druggable Targets. Handbook of Experimental Pharmacology. Berlin : Springer, 2018. (Handbook of Experimental Pharmacology).
@inbook{a70df958a7274afea52308c68001184d,
title = "Sphingosine Kinases as Druggable Targets",
abstract = "There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid sphingosine 1-phosphate, are involved in pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.",
author = "Susan Pyne and Adams, {David Roger} and Pyne, {Nigel J.}",
year = "2018",
month = "2",
day = "20",
doi = "10.1007/164_2018_96",
language = "English",
series = "Handbook of Experimental Pharmacology",
publisher = "Springer",
booktitle = "Handbook of Experimental Pharmacology",

}

Pyne, S, Adams, DR & Pyne, NJ 2018, Sphingosine Kinases as Druggable Targets. in Handbook of Experimental Pharmacology. Handbook of Experimental Pharmacology, Springer, Berlin. https://doi.org/10.1007/164_2018_96

Sphingosine Kinases as Druggable Targets. / Pyne, Susan; Adams, David Roger; Pyne, Nigel J.

Handbook of Experimental Pharmacology. Berlin : Springer, 2018. (Handbook of Experimental Pharmacology).

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

TY - CHAP

T1 - Sphingosine Kinases as Druggable Targets

AU - Pyne, Susan

AU - Adams, David Roger

AU - Pyne, Nigel J.

PY - 2018/2/20

Y1 - 2018/2/20

N2 - There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid sphingosine 1-phosphate, are involved in pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

AB - There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid sphingosine 1-phosphate, are involved in pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

U2 - 10.1007/164_2018_96

DO - 10.1007/164_2018_96

M3 - Chapter (peer-reviewed)

T3 - Handbook of Experimental Pharmacology

BT - Handbook of Experimental Pharmacology

PB - Springer

CY - Berlin

ER -

Pyne S, Adams DR, Pyne NJ. Sphingosine Kinases as Druggable Targets. In Handbook of Experimental Pharmacology. Berlin: Springer. 2018. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/164_2018_96